Safety of intermediate dose of low molecular weight heparin in COVID-19 patients
| Autor: | Patrizia Maria Baldini, Paola Mainquà, Alessandro Caraffa, Donatella Dennetta, Francesca Fulgenzi, M. Mancini, Antonio Polenta, Lorenzo Gasperoni, Gabriele Frausini, Massimo Mattioli, Luciano Mucci, Samuele Bedetta, Devis Benfaremo |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Male
Gastrointestinal bleeding medicine.medical_specialty Blood transfusion medicine.drug_class medicine.medical_treatment Low molecular weight heparin 030204 cardiovascular system & hematology Gastroenterology Article 03 medical and health sciences 0302 clinical medicine Internal medicine Coagulopathy Humans Medicine 030212 general & internal medicine Enoxaparin Aged Retrospective Studies Aged 80 and over Heparin SARS-CoV-2 business.industry Bleeding COVID-19 Thrombosis Pneumonia Hematology Middle Aged medicine.disease COVID-19 Drug Treatment Pulmonary embolism Italy Kidney Failure Chronic Female Safety business Cardiology and Cardiovascular Medicine Follow-Up Studies medicine.drug |
| Zdroj: | Journal of Thrombosis and Thrombolysis |
| ISSN: | 1573-742X 0929-5305 |
| DOI: | 10.1007/s11239-020-02243-z |
| Popis: | Coagulopathy represents one of the most important determinants of morbidity and mortality in coronavirus disease-19 (COVID-19). Whether standard thromboprophylaxis is sufficient or higher doses are needed, especially in severe patients, is unknown. To evaluate the safety of intermediate dose regimens of low-weight molecular heparin (LWMH) in COVID-19 patients with pneumonia, particularly in older patients. We retrospectively evaluated 105 hospitalized patients (61 M, 44 F; mean age 73.7 years) treated with subcutaneous enoxaparin: 80 mg/day in normal weight and mild-to-moderate impair or normal renal function; 40 mg/day in severe chronic renal failure or low bodyweight ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink